Biologics API MarketSize, Share & Industry Analysis, 2026-2034By Molecule TypeBy Expression SystemBy SourceBy Manufacturing ModeBy Scale of OperationBy Process TypeBy Bioreactor TechnologyBy Therapeutic AreaBy Route of AdministrationBy End User
Full title & scope — all 10 axes with their segments
Biologics API Market Size, Share & Industry Analysis, By Molecule Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell and Gene Therapy, Peptides and Oligonucleotides, Plasma-Derived Products), By Expression System (Mammalian Cells, Microbial, Insect Cells, Plant-Based, Cell-Free), By Source (Innovator Biologics, Biosimilars), By Manufacturing Mode (In-House Manufacturing, Outsourced), By Scale of Operation (Preclinical, Clinical, Commercial), By Process Type (Batch, Fed-Batch, Perfusion and Continuous), By Bioreactor Technology (Single-Use Systems, Stainless Steel Systems), By Therapeutic Area (Oncology, Autoimmune and Inflammatory Diseases, Infectious Diseases, Metabolic Disorders, Neurology, Rare and Genetic Diseases), By Route of Administration (Injectable, Oral, Inhalation, Topical), By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Development and Manufacturing Organizations, Academic and Research Institutes), and Regional Forecast, 2026-2034
Last Updated: Nov 2, 2026Format: PDFReport ID: CDI-248822
TOC
Full table of contents for the published report, chapter by chapter.
Full chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
1.1Strategic Imperatives
1.2Definition
1.3Biologics API Comparison By Segments
Chapter 2.Premium Insights
2.1Top 3 Trends to Watch
2.2Top 3 Strategies Followed by Major Players
2.3Top 3 Predictions by Contrive Datum Insights
2.4Top Investment Pockets
2.4.1Market Attractiveness Analysis, By Molecule Type
2.4.2Market Attractiveness Analysis, By Expression System
2.4.3Market Attractiveness Analysis, By Source
2.4.4Market Attractiveness Analysis, By Manufacturing Mode
2.4.5Market Attractiveness Analysis, By Scale of Operation
2.4.6Market Attractiveness Analysis, By Process Type
2.4.7Market Attractiveness Analysis, By Bioreactor Technology
2.4.8Market Attractiveness Analysis, By Therapeutic Area
2.4.9Market Attractiveness Analysis, By Route of Administration
2.4.10Market Attractiveness Analysis, By End User
2.5Key Market Participants — Intensity Mapping
2.6Insights From Primary Respondents
Chapter 3.Market Definition
Chapter 4.Research Methodology
4.1Research Approach
4.1.1Research Programs / Design
4.1.2Market Size Estimation
4.2Data Sources
4.2.1Secondary Sources
4.2.1.1Preliminary Data Mining
4.2.2Primary Sources
4.2.2.1Statistical Model
4.2.2.2Data Triangulation
4.2.2.3Research Objective
4.3Flow Of Methodology
4.4Top-Down / Bottom-Up Approach
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
6.1Market Focus & Value Proposition
6.1.1Target Customers, Priority Markets, and Core Value Proposition
6.1.2Product Differentiation and Positioning Logic
6.2Commercial Model & Pricing Strategy
6.2.1Pricing Approach and Value Capture
6.2.2Contracting, Bundling, and Monetization Framework
6.3Channels, Sales & Partnerships
6.3.1Direct and Indirect Channel Strategy
6.3.2Sales Execution Model and Strategic Partnerships
6.4Marketing, Launch & Execution Roadmap
6.4.1Marketing and Demand Generation Approach
6.4.2Launch Sequencing and Rollout Plan
6.5Operational Readiness & Governance KPIs
6.5.1Supply Chain and Operational Preparedness
6.5.2Regulatory Considerations, Risks, and Performance Tracking
Chapter 7.Market Trends, Strategy & Dynamics
7.1Trends Overview
7.2Strategic Overview
7.3Market Drivers
7.4Market Restraints
7.5Market Opportunities
7.6Market Challenges
7.7Impact Analysis of Market Dynamics
Chapter 8.Porter's Five Forces
8.1Bargaining Power of Suppliers
8.2Bargaining Power of Buyers
8.3Threat of New Entrants
8.4Threat of Substitutes
8.5Competitive Rivalry
Chapter 9.PESTEL Analysis
9.1Political
9.2Economic
9.3Social
9.4Technological
9.5Environmental
9.6Legal
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
12.1Macro-Economic Factors Overview
12.2Forecast Factors — Relevance and Impact
Chapter 13.Market Cost Analysis
13.1Key Raw Materials Analysis
13.1.1Key Raw Materials
13.1.2Price Trend of Key Raw Materials
13.1.3Key Suppliers of Raw Materials
13.1.4Market Concentration Rate of Raw Materials
13.1.5Raw Materials
13.1.6Labor Cost
Chapter 14.Market Supply-Side Analysis
14.1Raw Materials
14.2Price Trends
14.3Industry Chain
14.4Raw Materials Sourcing
14.5Raw Materials Sources of Major Manufacturers
14.6Downstream Buyers
Chapter 15.Global Biologics API Market Size & Projections, 2020–2034, Revenue (USD Billion)
15.1Global Biologics API Market Size — Total
15.2Market Size, by Segment (By Molecule Type, By Expression System, By Source, By Manufacturing Mode, By Scale of Operation, By Process Type, By Bioreactor Technology, By Therapeutic Area, By Route of Administration, By End User)
Chapter 16.Global Biologics API Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
16.1Introduction
16.2Global Biologics API Market Size, By Molecule Type, 2020–2034, Revenue (USD Billion)
16.3Global Biologics API Market Share, By Molecule Type (%)
16.3.1Monoclonal Antibodies
16.3.1.1Market Size, By Monoclonal Antibodies, 2020–2034, Revenue (USD Billion)
16.3.1.2Monoclonal Antibodies Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
16.3.1.3Monoclonal Antibodies Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
16.3.1.4Monoclonal Antibodies Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
16.3.1.5Monoclonal Antibodies Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
16.3.1.6Monoclonal Antibodies Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
16.3.1.7Monoclonal Antibodies Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
16.3.1.8Monoclonal Antibodies Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
16.3.1.9Monoclonal Antibodies Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
16.3.1.10Monoclonal Antibodies Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
16.3.2Recombinant Proteins
16.3.3Vaccines
16.3.4Cell and Gene Therapy
16.3.5Peptides and Oligonucleotides
16.3.6Plasma-Derived Products
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 16.3.1 (Monoclonal Antibodies).
Chapter 17.Global Biologics API Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
17.1Introduction
17.2Global Biologics API Market Size, By Expression System, 2020–2034, Revenue (USD Billion)
17.3Global Biologics API Market Share, By Expression System (%)
17.3.1Mammalian Cells
17.3.1.1Market Size, By Mammalian Cells, 2020–2034, Revenue (USD Billion)
17.3.1.2Mammalian Cells Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
17.3.1.3Mammalian Cells Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
17.3.1.4Mammalian Cells Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
17.3.1.5Mammalian Cells Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
17.3.1.6Mammalian Cells Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
17.3.1.7Mammalian Cells Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
17.3.1.8Mammalian Cells Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
17.3.1.9Mammalian Cells Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
17.3.1.10Mammalian Cells Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
17.3.2Microbial
17.3.3Insect Cells
17.3.4Plant-Based
17.3.5Cell-Free
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 17.3.1 (Mammalian Cells).
Chapter 18.Global Biologics API Market Overview, By Source, 2020–2034, Revenue (USD Billion)
18.1Introduction
18.2Global Biologics API Market Size, By Source, 2020–2034, Revenue (USD Billion)
18.3Global Biologics API Market Share, By Source (%)
18.3.1Innovator Biologics
18.3.1.1Market Size, By Innovator Biologics, 2020–2034, Revenue (USD Billion)
18.3.1.2Innovator Biologics Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
18.3.1.3Innovator Biologics Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
18.3.1.4Innovator Biologics Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
18.3.1.5Innovator Biologics Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
18.3.1.6Innovator Biologics Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
18.3.1.7Innovator Biologics Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
18.3.1.8Innovator Biologics Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
18.3.1.9Innovator Biologics Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
18.3.1.10Innovator Biologics Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
18.3.2Biosimilars
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 18.3.1 (Innovator Biologics).
Chapter 19.Global Biologics API Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
19.1Introduction
19.2Global Biologics API Market Size, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
19.3Global Biologics API Market Share, By Manufacturing Mode (%)
19.3.1In-House Manufacturing
19.3.1.1Market Size, By In-House Manufacturing, 2020–2034, Revenue (USD Billion)
19.3.1.2In-House Manufacturing Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
19.3.1.3In-House Manufacturing Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
19.3.1.4In-House Manufacturing Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
19.3.1.5In-House Manufacturing Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
19.3.1.6In-House Manufacturing Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
19.3.1.7In-House Manufacturing Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
19.3.1.8In-House Manufacturing Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
19.3.1.9In-House Manufacturing Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
19.3.1.10In-House Manufacturing Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
19.3.2Outsourced (CDMO)
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 19.3.1 (In-House Manufacturing).
Chapter 20.Global Biologics API Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
20.1Introduction
20.2Global Biologics API Market Size, By Scale of Operation, 2020–2034, Revenue (USD Billion)
20.3Global Biologics API Market Share, By Scale of Operation (%)
20.3.1Preclinical
20.3.1.1Market Size, By Preclinical, 2020–2034, Revenue (USD Billion)
20.3.1.2Preclinical Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
20.3.1.3Preclinical Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
20.3.1.4Preclinical Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
20.3.1.5Preclinical Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
20.3.1.6Preclinical Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
20.3.1.7Preclinical Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
20.3.1.8Preclinical Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
20.3.1.9Preclinical Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
20.3.1.10Preclinical Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
20.3.2Clinical
20.3.3Commercial
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 20.3.1 (Preclinical).
Chapter 21.Global Biologics API Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
21.1Introduction
21.2Global Biologics API Market Size, By Process Type, 2020–2034, Revenue (USD Billion)
21.3Global Biologics API Market Share, By Process Type (%)
21.3.1Batch
21.3.1.1Market Size, By Batch, 2020–2034, Revenue (USD Billion)
21.3.1.2Batch Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
21.3.1.3Batch Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
21.3.1.4Batch Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
21.3.1.5Batch Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
21.3.1.6Batch Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
21.3.1.7Batch Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
21.3.1.8Batch Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
21.3.1.9Batch Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
21.3.1.10Batch Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
21.3.2Fed-Batch
21.3.3Perfusion and Continuous
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 21.3.1 (Batch).
Chapter 22.Global Biologics API Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
22.1Introduction
22.2Global Biologics API Market Size, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
22.3Global Biologics API Market Share, By Bioreactor Technology (%)
22.3.1Single-Use Systems
22.3.1.1Market Size, By Single-Use Systems, 2020–2034, Revenue (USD Billion)
22.3.1.2Single-Use Systems Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
22.3.1.3Single-Use Systems Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
22.3.1.4Single-Use Systems Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
22.3.1.5Single-Use Systems Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
22.3.1.6Single-Use Systems Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
22.3.1.7Single-Use Systems Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
22.3.1.8Single-Use Systems Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
22.3.1.9Single-Use Systems Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
22.3.1.10Single-Use Systems Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
22.3.2Stainless Steel Systems
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 22.3.1 (Single-Use Systems).
Chapter 23.Global Biologics API Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
23.1Introduction
23.2Global Biologics API Market Size, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
23.3Global Biologics API Market Share, By Therapeutic Area (%)
23.3.1Oncology
23.3.1.1Market Size, By Oncology, 2020–2034, Revenue (USD Billion)
23.3.1.2Oncology Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
23.3.1.3Oncology Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
23.3.1.4Oncology Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
23.3.1.5Oncology Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
23.3.1.6Oncology Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
23.3.1.7Oncology Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
23.3.1.8Oncology Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
23.3.1.9Oncology Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
23.3.1.10Oncology Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
23.3.2Autoimmune and Inflammatory Diseases
23.3.3Infectious Diseases
23.3.4Metabolic Disorders
23.3.5Neurology
23.3.6Rare and Genetic Diseases
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 23.3.1 (Oncology).
Chapter 24.Global Biologics API Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
24.1Introduction
24.2Global Biologics API Market Size, By Route of Administration, 2020–2034, Revenue (USD Billion)
24.3Global Biologics API Market Share, By Route of Administration (%)
24.3.1Injectable
24.3.1.1Market Size, By Injectable, 2020–2034, Revenue (USD Billion)
24.3.1.2Injectable Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
24.3.1.3Injectable Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
24.3.1.4Injectable Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
24.3.1.5Injectable Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
24.3.1.6Injectable Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
24.3.1.7Injectable Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
24.3.1.8Injectable Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
24.3.1.9Injectable Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
24.3.1.10Injectable Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
24.3.2Oral
24.3.3Inhalation
24.3.4Topical
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 24.3.1 (Injectable).
Chapter 25.Global Biologics API Market Overview, By End User, 2020–2034, Revenue (USD Billion)
25.1Introduction
25.2Global Biologics API Market Size, By End User, 2020–2034, Revenue (USD Billion)
25.3Global Biologics API Market Share, By End User (%)
25.3.1Pharmaceutical Companies
25.3.1.1Market Size, By Pharmaceutical Companies, 2020–2034, Revenue (USD Billion)
25.3.1.2Pharmaceutical Companies Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
25.3.1.3Pharmaceutical Companies Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
25.3.1.4Pharmaceutical Companies Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
25.3.1.5Pharmaceutical Companies Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
25.3.1.6Pharmaceutical Companies Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
25.3.1.7Pharmaceutical Companies Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
25.3.1.8Pharmaceutical Companies Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
25.3.1.9Pharmaceutical Companies Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
25.3.1.10Pharmaceutical Companies Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
25.3.2Biotechnology Companies
25.3.3Contract Development and Manufacturing Organizations
25.3.4Academic and Research Institutes
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 25.3.1 (Pharmaceutical Companies).
Chapter 26.Global Biologics API Market Size — Segment Comparison
Chapter 27.Global Biologics API Geography Overview, 2020–2034, Revenue (USD Billion)
27.1Revenue, By Geography, 2020–2034, Revenue (USD Billion)
27.2Share, By Geography, 2020–2034 (%)
27.3Share, By Geography Analysis, 2025, Market Share and CAGR
27.4Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Chapter 28.North America Biologics API Market Deep-Dive, 2020–2034, Revenue (USD Billion)
28.1Overview, 2020–2034
28.2Size and Projections, 2020–2034, Revenue (USD Billion)
28.2.1By Molecule Type, 2020–2034
28.2.2By Expression System, 2020–2034
28.2.3By Source, 2020–2034
28.2.4By Manufacturing Mode, 2020–2034
28.2.5By Scale of Operation, 2020–2034
28.2.6By Process Type, 2020–2034
28.2.7By Bioreactor Technology, 2020–2034
28.2.8By Therapeutic Area, 2020–2034
28.2.9By Route of Administration, 2020–2034
28.2.10By End User, 2020–2034
28.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
28.3.1US
28.3.1.1US — Key Country Dynamics
28.3.1.2US — Regulatory Framework
28.3.1.3US — Competitive Scenario
28.3.1.4US — Market Overview, 2020–2034, Revenue (USD Billion)
28.3.1.5US — Market Size and Projections, 2020–2034, Revenue (USD Billion)
28.3.1.6US Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
28.3.1.7US Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
28.3.1.8US Market Overview, By Source, 2020–2034, Revenue (USD Billion)
28.3.1.9US Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
28.3.1.10US Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
28.3.1.11US Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
28.3.1.12US Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
28.3.1.13US Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
28.3.1.14US Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
28.3.1.15US Market Overview, By End User, 2020–2034, Revenue (USD Billion)
28.3.2Canada
28.3.3Mexico
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 28.3.1 (US).
Chapter 29.Europe Biologics API Market Deep-Dive, 2020–2034, Revenue (USD Billion)
29.1Overview, 2020–2034
29.2Size and Projections, 2020–2034, Revenue (USD Billion)
29.2.1By Molecule Type, 2020–2034
29.2.2By Expression System, 2020–2034
29.2.3By Source, 2020–2034
29.2.4By Manufacturing Mode, 2020–2034
29.2.5By Scale of Operation, 2020–2034
29.2.6By Process Type, 2020–2034
29.2.7By Bioreactor Technology, 2020–2034
29.2.8By Therapeutic Area, 2020–2034
29.2.9By Route of Administration, 2020–2034
29.2.10By End User, 2020–2034
29.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
29.3.1Germany
29.3.1.1Germany — Key Country Dynamics
29.3.1.2Germany — Regulatory Framework
29.3.1.3Germany — Competitive Scenario
29.3.1.4Germany — Market Overview, 2020–2034, Revenue (USD Billion)
29.3.1.5Germany — Market Size and Projections, 2020–2034, Revenue (USD Billion)
29.3.1.6Germany Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
29.3.1.7Germany Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
29.3.1.8Germany Market Overview, By Source, 2020–2034, Revenue (USD Billion)
29.3.1.9Germany Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
29.3.1.10Germany Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
29.3.1.11Germany Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
29.3.1.12Germany Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
29.3.1.13Germany Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
29.3.1.14Germany Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
29.3.1.15Germany Market Overview, By End User, 2020–2034, Revenue (USD Billion)
29.3.2France
29.3.3Italy
29.3.4Spain
29.3.5UK
29.3.6Nordic Countries
29.3.7Benelux Union
29.3.8Rest of Europe
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 29.3.1 (Germany).
Chapter 30.Asia Pacific Biologics API Market Deep-Dive, 2020–2034, Revenue (USD Billion)
30.1Overview, 2020–2034
30.2Size and Projections, 2020–2034, Revenue (USD Billion)
30.2.1By Molecule Type, 2020–2034
30.2.2By Expression System, 2020–2034
30.2.3By Source, 2020–2034
30.2.4By Manufacturing Mode, 2020–2034
30.2.5By Scale of Operation, 2020–2034
30.2.6By Process Type, 2020–2034
30.2.7By Bioreactor Technology, 2020–2034
30.2.8By Therapeutic Area, 2020–2034
30.2.9By Route of Administration, 2020–2034
30.2.10By End User, 2020–2034
30.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
30.3.1India
30.3.1.1India — Key Country Dynamics
30.3.1.2India — Regulatory Framework
30.3.1.3India — Competitive Scenario
30.3.1.4India — Market Overview, 2020–2034, Revenue (USD Billion)
30.3.1.5India — Market Size and Projections, 2020–2034, Revenue (USD Billion)
30.3.1.6India Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
30.3.1.7India Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
30.3.1.8India Market Overview, By Source, 2020–2034, Revenue (USD Billion)
30.3.1.9India Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
30.3.1.10India Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
30.3.1.11India Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
30.3.1.12India Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
30.3.1.13India Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
30.3.1.14India Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
30.3.1.15India Market Overview, By End User, 2020–2034, Revenue (USD Billion)
30.3.2Australia
30.3.3China
30.3.4China (Taiwan)
30.3.5Japan
30.3.6South Korea
30.3.7Southeast Asia
30.3.8Indonesia
30.3.9Thailand
30.3.10Malaysia
30.3.11Singapore
30.3.12Rest of Asia Pacific
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 30.3.1 (India).
Chapter 31.Latin America Biologics API Market Deep-Dive, 2020–2034, Revenue (USD Billion)
31.1Overview, 2020–2034
31.2Size and Projections, 2020–2034, Revenue (USD Billion)
31.2.1By Molecule Type, 2020–2034
31.2.2By Expression System, 2020–2034
31.2.3By Source, 2020–2034
31.2.4By Manufacturing Mode, 2020–2034
31.2.5By Scale of Operation, 2020–2034
31.2.6By Process Type, 2020–2034
31.2.7By Bioreactor Technology, 2020–2034
31.2.8By Therapeutic Area, 2020–2034
31.2.9By Route of Administration, 2020–2034
31.2.10By End User, 2020–2034
31.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
31.3.1Brazil
31.3.1.1Brazil — Key Country Dynamics
31.3.1.2Brazil — Regulatory Framework
31.3.1.3Brazil — Competitive Scenario
31.3.1.4Brazil — Market Overview, 2020–2034, Revenue (USD Billion)
31.3.1.5Brazil — Market Size and Projections, 2020–2034, Revenue (USD Billion)
31.3.1.6Brazil Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
31.3.1.7Brazil Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
31.3.1.8Brazil Market Overview, By Source, 2020–2034, Revenue (USD Billion)
31.3.1.9Brazil Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
31.3.1.10Brazil Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
31.3.1.11Brazil Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
31.3.1.12Brazil Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
31.3.1.13Brazil Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
31.3.1.14Brazil Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
31.3.1.15Brazil Market Overview, By End User, 2020–2034, Revenue (USD Billion)
31.3.2Argentina
31.3.3Rest of Latin America
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 31.3.1 (Brazil).
Chapter 32.Middle East and Africa Biologics API Market Deep-Dive, 2020–2034, Revenue (USD Billion)
32.1Overview, 2020–2034
32.2Size and Projections, 2020–2034, Revenue (USD Billion)
32.2.1By Molecule Type, 2020–2034
32.2.2By Expression System, 2020–2034
32.2.3By Source, 2020–2034
32.2.4By Manufacturing Mode, 2020–2034
32.2.5By Scale of Operation, 2020–2034
32.2.6By Process Type, 2020–2034
32.2.7By Bioreactor Technology, 2020–2034
32.2.8By Therapeutic Area, 2020–2034
32.2.9By Route of Administration, 2020–2034
32.2.10By End User, 2020–2034
32.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
32.3.1GCC
32.3.1.1GCC — Key Country Dynamics
32.3.1.2GCC — Regulatory Framework
32.3.1.3GCC — Competitive Scenario
32.3.1.4GCC — Market Overview, 2020–2034, Revenue (USD Billion)
32.3.1.5GCC — Market Size and Projections, 2020–2034, Revenue (USD Billion)
32.3.1.6GCC Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
32.3.1.7GCC Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
32.3.1.8GCC Market Overview, By Source, 2020–2034, Revenue (USD Billion)
32.3.1.9GCC Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
32.3.1.10GCC Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
32.3.1.11GCC Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
32.3.1.12GCC Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
32.3.1.13GCC Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
32.3.1.14GCC Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
32.3.1.15GCC Market Overview, By End User, 2020–2034, Revenue (USD Billion)
32.3.2Egypt
32.3.3South Africa
32.3.4Rest of the Middle East & Africa
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 32.3.1 (GCC).
Chapter 33.Application / Use-Case Analysis
Chapter 34.Vendor Capability Scorecard
Chapter 35.Scenario Forecasts
35.1Bull-case Trajectory
35.2Base-case Trajectory
35.3Bear-case Trajectory
Chapter 36.Top 10 Key Clients of Top 10 Players
Chapter 37.Top 10 Suppliers
Chapter 38.Competitive Landscape
38.1Lonza Group AG
38.2Samsung Biologics Co., Ltd.
38.3WuXi Biologics (Cayman) Inc.
38.4Boehringer Ingelheim International GmbH
38.5Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation)
38.6Thermo Fisher Scientific Inc.
38.7Catalent, Inc.
38.8AGC Biologics
38.9F. Hoffmann-La Roche Ltd (Genentech, Inc.)
38.10Amgen Inc.
38.11Celltrion, Inc.
38.12Sandoz Group AG
38.13Merck KGaA
38.14Pfizer Inc.
38.15Biocon Biologics Ltd.
38.16Rentschler Biopharma SE
38.17Polpharma Biologics S.A.
38.18Abzena Ltd.
38.19Emergent BioSolutions Inc.
38.20Dr. Reddy's Laboratories Ltd.
38.21Gedeon Richter Plc
38.22Resilience (National Resilience, Inc.)
38.23Cytovance Biologics, Inc.
38.24Wacker Biotech GmbH
38.25Bachem Holding AG
Chapter 39.Partnerships & M&A
Chapter 40.Key Vendor Analysis
40.1Lonza Group AG
40.2Samsung Biologics Co., Ltd.
40.3WuXi Biologics (Cayman) Inc.
40.4Boehringer Ingelheim International GmbH
40.5Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation)
40.6Thermo Fisher Scientific Inc.
40.7Catalent, Inc.
40.8AGC Biologics
40.9F. Hoffmann-La Roche Ltd (Genentech, Inc.)
40.10Amgen Inc.
40.11Celltrion, Inc.
40.12Sandoz Group AG
40.13Merck KGaA
40.14Pfizer Inc.
40.15Biocon Biologics Ltd.
40.16Rentschler Biopharma SE
40.17Polpharma Biologics S.A.
40.18Abzena Ltd.
40.19Emergent BioSolutions Inc.
40.20Dr. Reddy's Laboratories Ltd.
40.21Gedeon Richter Plc
40.22Resilience (National Resilience, Inc.)
40.23Cytovance Biologics, Inc.
40.24Wacker Biotech GmbH
40.25Bachem Holding AG
Chapter 41.Marketing Strategy Analysis, Distributors & Traders
Chapter 42.Outlook of the Market
Chapter 43.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
Figure 2.1Top 3 Trends to Watch
Figure 2.4Top Investment Pockets
Figure 2.4.1Market Attractiveness Analysis, By Molecule Type
Figure 2.4.2Market Attractiveness Analysis, By Expression System
Figure 2.4.3Market Attractiveness Analysis, By Source
Figure 2.4.4Market Attractiveness Analysis, By Manufacturing Mode
Figure 2.4.5Market Attractiveness Analysis, By Scale of Operation
Figure 2.4.6Market Attractiveness Analysis, By Process Type
Figure 2.4.7Market Attractiveness Analysis, By Bioreactor Technology
Figure 2.4.8Market Attractiveness Analysis, By Therapeutic Area
Figure 2.4.9Market Attractiveness Analysis, By Route of Administration
Figure 2.4.10Market Attractiveness Analysis, By End User
Figure 2.5Key Market Participants — Intensity Mapping
Figure 4.2.2.2Data Triangulation
Figure 4.3Flow Of Methodology
Figure 4.4Top-Down / Bottom-Up Approach
Figure 6.1.2Product Differentiation and Positioning Logic
Figure 16.3Global Biologics API Market Share, By Molecule Type (%)
Figure 17.3Global Biologics API Market Share, By Expression System (%)
Figure 18.3Global Biologics API Market Share, By Source (%)
Figure 19.3Global Biologics API Market Share, By Manufacturing Mode (%)
Figure 20.3Global Biologics API Market Share, By Scale of Operation (%)
Figure 21.3Global Biologics API Market Share, By Process Type (%)
Figure 22.3Global Biologics API Market Share, By Bioreactor Technology (%)
Figure 23.3Global Biologics API Market Share, By Therapeutic Area (%)
Figure 24.3Global Biologics API Market Share, By Route of Administration (%)
Figure 25.3Global Biologics API Market Share, By End User (%)
Figure 27.2Share, By Geography, 2020–2034 (%)
Figure 27.3Share, By Geography Analysis, 2025, Market Share and CAGR
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Table 1.3Biologics API Comparison By Segments
Table 4.1.2Market Size Estimation
Table 15.1Global Biologics API Market Size — Total
Table 15.2Market Size, by Segment (By Molecule Type, By Expression System, By Source, By Manufacturing Mode, By Scale of Operation, By Process Type, By Bioreactor Technology, By Therapeutic Area, By Route of Administration, By End User)
Table 16.2Global Biologics API Market Size, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 16.3.1.1Market Size, By Monoclonal Antibodies, 2020–2034, Revenue (USD Billion)
Table 16.3.1.2Monoclonal Antibodies Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
Table 16.3.1.3Monoclonal Antibodies Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
Table 16.3.1.4Monoclonal Antibodies Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 16.3.1.5Monoclonal Antibodies Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 16.3.1.6Monoclonal Antibodies Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
Table 16.3.1.7Monoclonal Antibodies Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 16.3.1.8Monoclonal Antibodies Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 16.3.1.9Monoclonal Antibodies Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 16.3.1.10Monoclonal Antibodies Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 17.2Global Biologics API Market Size, By Expression System, 2020–2034, Revenue (USD Billion)
Table 17.3.1.1Market Size, By Mammalian Cells, 2020–2034, Revenue (USD Billion)
Table 17.3.1.2Mammalian Cells Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 17.3.1.3Mammalian Cells Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
Table 17.3.1.4Mammalian Cells Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 17.3.1.5Mammalian Cells Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 17.3.1.6Mammalian Cells Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
Table 17.3.1.7Mammalian Cells Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 17.3.1.8Mammalian Cells Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 17.3.1.9Mammalian Cells Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 17.3.1.10Mammalian Cells Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 18.2Global Biologics API Market Size, By Source, 2020–2034, Revenue (USD Billion)
Table 18.3.1.1Market Size, By Innovator Biologics, 2020–2034, Revenue (USD Billion)
Table 18.3.1.2Innovator Biologics Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 18.3.1.3Innovator Biologics Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
Table 18.3.1.4Innovator Biologics Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 18.3.1.5Innovator Biologics Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 18.3.1.6Innovator Biologics Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
Table 18.3.1.7Innovator Biologics Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 18.3.1.8Innovator Biologics Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 18.3.1.9Innovator Biologics Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 18.3.1.10Innovator Biologics Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 19.2Global Biologics API Market Size, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 19.3.1.1Market Size, By In-House Manufacturing, 2020–2034, Revenue (USD Billion)
Table 19.3.1.2In-House Manufacturing Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 19.3.1.3In-House Manufacturing Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
Table 19.3.1.4In-House Manufacturing Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
Table 19.3.1.5In-House Manufacturing Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 19.3.1.6In-House Manufacturing Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
Table 19.3.1.7In-House Manufacturing Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 19.3.1.8In-House Manufacturing Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 19.3.1.9In-House Manufacturing Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 19.3.1.10In-House Manufacturing Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 20.2Global Biologics API Market Size, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 20.3.1.1Market Size, By Preclinical, 2020–2034, Revenue (USD Billion)
Table 20.3.1.2Preclinical Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 20.3.1.3Preclinical Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
Table 20.3.1.4Preclinical Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
Table 20.3.1.5Preclinical Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 20.3.1.6Preclinical Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
Table 20.3.1.7Preclinical Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 20.3.1.8Preclinical Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 20.3.1.9Preclinical Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 20.3.1.10Preclinical Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 21.2Global Biologics API Market Size, By Process Type, 2020–2034, Revenue (USD Billion)
Table 21.3.1.1Market Size, By Batch, 2020–2034, Revenue (USD Billion)
Table 21.3.1.2Batch Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 21.3.1.3Batch Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
Table 21.3.1.4Batch Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
Table 21.3.1.5Batch Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 21.3.1.6Batch Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 21.3.1.7Batch Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 21.3.1.8Batch Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 21.3.1.9Batch Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 21.3.1.10Batch Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 22.2Global Biologics API Market Size, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 22.3.1.1Market Size, By Single-Use Systems, 2020–2034, Revenue (USD Billion)
Table 22.3.1.2Single-Use Systems Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 22.3.1.3Single-Use Systems Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
Table 22.3.1.4Single-Use Systems Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
Table 22.3.1.5Single-Use Systems Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 22.3.1.6Single-Use Systems Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 22.3.1.7Single-Use Systems Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
Table 22.3.1.8Single-Use Systems Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 22.3.1.9Single-Use Systems Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 22.3.1.10Single-Use Systems Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 23.2Global Biologics API Market Size, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 23.3.1.1Market Size, By Oncology, 2020–2034, Revenue (USD Billion)
Table 23.3.1.2Oncology Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 23.3.1.3Oncology Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
Table 23.3.1.4Oncology Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
Table 23.3.1.5Oncology Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 23.3.1.6Oncology Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 23.3.1.7Oncology Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
Table 23.3.1.8Oncology Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 23.3.1.9Oncology Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 23.3.1.10Oncology Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 24.2Global Biologics API Market Size, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 24.3.1.1Market Size, By Injectable, 2020–2034, Revenue (USD Billion)
Table 24.3.1.2Injectable Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 24.3.1.3Injectable Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
Table 24.3.1.4Injectable Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
Table 24.3.1.5Injectable Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 24.3.1.6Injectable Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 24.3.1.7Injectable Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
Table 24.3.1.8Injectable Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 24.3.1.9Injectable Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 24.3.1.10Injectable Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 25.2Global Biologics API Market Size, By End User, 2020–2034, Revenue (USD Billion)
Table 25.3.1.1Market Size, By Pharmaceutical Companies, 2020–2034, Revenue (USD Billion)
Table 25.3.1.2Pharmaceutical Companies Size and Projections, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 25.3.1.3Pharmaceutical Companies Size and Projections, By Expression System, 2020–2034, Revenue (USD Billion)
Table 25.3.1.4Pharmaceutical Companies Size and Projections, By Source, 2020–2034, Revenue (USD Billion)
Table 25.3.1.5Pharmaceutical Companies Size and Projections, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 25.3.1.6Pharmaceutical Companies Size and Projections, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 25.3.1.7Pharmaceutical Companies Size and Projections, By Process Type, 2020–2034, Revenue (USD Billion)
Table 25.3.1.8Pharmaceutical Companies Size and Projections, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 25.3.1.9Pharmaceutical Companies Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 25.3.1.10Pharmaceutical Companies Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 27.1Revenue, By Geography, 2020–2034, Revenue (USD Billion)
Table 27.4Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 28.1Overview, 2020–2034
Table 28.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 28.2.1By Molecule Type, 2020–2034
Table 28.2.2By Expression System, 2020–2034
Table 28.2.3By Source, 2020–2034
Table 28.2.4By Manufacturing Mode, 2020–2034
Table 28.2.5By Scale of Operation, 2020–2034
Table 28.2.6By Process Type, 2020–2034
Table 28.2.7By Bioreactor Technology, 2020–2034
Table 28.2.8By Therapeutic Area, 2020–2034
Table 28.2.9By Route of Administration, 2020–2034
Table 28.2.10By End User, 2020–2034
Table 28.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 28.3.1.4US — Market Overview, 2020–2034, Revenue (USD Billion)
Table 28.3.1.5US — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 28.3.1.6US Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 28.3.1.7US Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
Table 28.3.1.8US Market Overview, By Source, 2020–2034, Revenue (USD Billion)
Table 28.3.1.9US Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 28.3.1.10US Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 28.3.1.11US Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
Table 28.3.1.12US Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 28.3.1.13US Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 28.3.1.14US Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 28.3.1.15US Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 29.1Overview, 2020–2034
Table 29.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 29.2.1By Molecule Type, 2020–2034
Table 29.2.2By Expression System, 2020–2034
Table 29.2.3By Source, 2020–2034
Table 29.2.4By Manufacturing Mode, 2020–2034
Table 29.2.5By Scale of Operation, 2020–2034
Table 29.2.6By Process Type, 2020–2034
Table 29.2.7By Bioreactor Technology, 2020–2034
Table 29.2.8By Therapeutic Area, 2020–2034
Table 29.2.9By Route of Administration, 2020–2034
Table 29.2.10By End User, 2020–2034
Table 29.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 29.3.1.4Germany — Market Overview, 2020–2034, Revenue (USD Billion)
Table 29.3.1.5Germany — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 29.3.1.6Germany Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 29.3.1.7Germany Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
Table 29.3.1.8Germany Market Overview, By Source, 2020–2034, Revenue (USD Billion)
Table 29.3.1.9Germany Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 29.3.1.10Germany Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 29.3.1.11Germany Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
Table 29.3.1.12Germany Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 29.3.1.13Germany Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 29.3.1.14Germany Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 29.3.1.15Germany Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 30.1Overview, 2020–2034
Table 30.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 30.2.1By Molecule Type, 2020–2034
Table 30.2.2By Expression System, 2020–2034
Table 30.2.3By Source, 2020–2034
Table 30.2.4By Manufacturing Mode, 2020–2034
Table 30.2.5By Scale of Operation, 2020–2034
Table 30.2.6By Process Type, 2020–2034
Table 30.2.7By Bioreactor Technology, 2020–2034
Table 30.2.8By Therapeutic Area, 2020–2034
Table 30.2.9By Route of Administration, 2020–2034
Table 30.2.10By End User, 2020–2034
Table 30.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 30.3.1.4India — Market Overview, 2020–2034, Revenue (USD Billion)
Table 30.3.1.5India — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 30.3.1.6India Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 30.3.1.7India Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
Table 30.3.1.8India Market Overview, By Source, 2020–2034, Revenue (USD Billion)
Table 30.3.1.9India Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 30.3.1.10India Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 30.3.1.11India Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
Table 30.3.1.12India Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 30.3.1.13India Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 30.3.1.14India Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 30.3.1.15India Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 31.1Overview, 2020–2034
Table 31.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 31.2.1By Molecule Type, 2020–2034
Table 31.2.2By Expression System, 2020–2034
Table 31.2.3By Source, 2020–2034
Table 31.2.4By Manufacturing Mode, 2020–2034
Table 31.2.5By Scale of Operation, 2020–2034
Table 31.2.6By Process Type, 2020–2034
Table 31.2.7By Bioreactor Technology, 2020–2034
Table 31.2.8By Therapeutic Area, 2020–2034
Table 31.2.9By Route of Administration, 2020–2034
Table 31.2.10By End User, 2020–2034
Table 31.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 31.3.1.4Brazil — Market Overview, 2020–2034, Revenue (USD Billion)
Table 31.3.1.5Brazil — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 31.3.1.6Brazil Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 31.3.1.7Brazil Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
Table 31.3.1.8Brazil Market Overview, By Source, 2020–2034, Revenue (USD Billion)
Table 31.3.1.9Brazil Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 31.3.1.10Brazil Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 31.3.1.11Brazil Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
Table 31.3.1.12Brazil Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 31.3.1.13Brazil Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 31.3.1.14Brazil Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 31.3.1.15Brazil Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 32.1Overview, 2020–2034
Table 32.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 32.2.1By Molecule Type, 2020–2034
Table 32.2.2By Expression System, 2020–2034
Table 32.2.3By Source, 2020–2034
Table 32.2.4By Manufacturing Mode, 2020–2034
Table 32.2.5By Scale of Operation, 2020–2034
Table 32.2.6By Process Type, 2020–2034
Table 32.2.7By Bioreactor Technology, 2020–2034
Table 32.2.8By Therapeutic Area, 2020–2034
Table 32.2.9By Route of Administration, 2020–2034
Table 32.2.10By End User, 2020–2034
Table 32.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 32.3.1.4GCC — Market Overview, 2020–2034, Revenue (USD Billion)
Table 32.3.1.5GCC — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 32.3.1.6GCC Market Overview, By Molecule Type, 2020–2034, Revenue (USD Billion)
Table 32.3.1.7GCC Market Overview, By Expression System, 2020–2034, Revenue (USD Billion)
Table 32.3.1.8GCC Market Overview, By Source, 2020–2034, Revenue (USD Billion)
Table 32.3.1.9GCC Market Overview, By Manufacturing Mode, 2020–2034, Revenue (USD Billion)
Table 32.3.1.10GCC Market Overview, By Scale of Operation, 2020–2034, Revenue (USD Billion)
Table 32.3.1.11GCC Market Overview, By Process Type, 2020–2034, Revenue (USD Billion)
Table 32.3.1.12GCC Market Overview, By Bioreactor Technology, 2020–2034, Revenue (USD Billion)
Table 32.3.1.13GCC Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 32.3.1.14GCC Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 32.3.1.15GCC Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Scope
Questions This Report Answers
6 questions01
What is the market size and growth rate, globally and by region?
02
How is the market segmented, and which segments lead?
03
Which regions and countries are covered, and how do they compare?
04
What are the key drivers, restraints, opportunities and challenges?
05
Who are the leading companies operating in this market?
06
What trends are expected to shape the market through the forecast period?
Questions
Frequently Asked Questions
01What is the Biologics API Market projected to reach?
USD 138.6 USD Billion by 2034, CAGR 7.8%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 42% of global revenue through 2034.
05Which segment leads the market?
Monoclonal Antibodies is the largest line by molecule type, at 46% of revenue in 2025.
06Who are the key companies profiled?
Lonza Group AG, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation), Thermo Fisher Scientific Inc., Catalent, Inc., AGC Biologics, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Amgen Inc., Celltrion, Inc., Sandoz Group AG, Merck KGaA, Pfizer Inc., Biocon Biologics Ltd., Rentschler Biopharma SE, Polpharma Biologics S.A., Abzena Ltd., Emergent BioSolutions Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc, Resilience (National Resilience, Inc.), Cytovance Biologics, Inc., Wacker Biotech GmbH, Bachem Holding AG. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
425+
Dedicated research analysts
1,200+
Reports published
Why CDI
Why choose CDI
Data triangulated across primary and secondary sources
Complimentary analyst call included with every purchase
Custom data cuts and post-purchase support available
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.
Explore
Related Reports
Pharmaceuticals & Biotech
Continuous Bioprocessing Market
USD 1220 Mn by 2034, CAGR 14.33%
Pharmaceuticals & Biotech
Clinical Trial Supplies Market
USD 10.3 Bn by 2034, CAGR 8.3%
Pharmaceuticals & Biotech
RNA Editing Market
USD 9.25 Bn by 2034, CAGR 19%
Pharmaceuticals & Biotech
Hospital Injectable Drugs Market
USD 1171.92 Bn by 2034, CAGR 7.6%
Pharmaceuticals & Biotech
Peptide Therapeutics Market
USD 291.5 Bn by 2034, CAGR 8.93%
Pharmaceuticals & Biotech
Biologics Market
USD 1051 Bn by 2034, CAGR 8.68%